These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 30616548)

  • 1. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis.
    Drozdz M; Weigert A; Silva F; Frazão J; Alsuwaida A; Krishnan M; Kleophas W; Brzosko S; Johansson FK; Jacobson SH
    BMC Nephrol; 2019 Jan; 20(1):5. PubMed ID: 30616548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.
    Macdougall IC; White C; Anker SD; Bhandari S; Farrington K; Kalra PA; McMurray JJV; Murray H; Steenkamp R; Tomson CRV; Wheeler DC; Winearls CG; Ford I;
    Am J Nephrol; 2018; 48(4):260-268. PubMed ID: 30304714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing.
    Diebold M; Kistler AD
    BMC Nephrol; 2019 Mar; 20(1):76. PubMed ID: 30823916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients.
    Bataille S; Pelletier M; Sallée M; Berland Y; McKay N; Duval A; Gentile S; Mouelhi Y; Brunet P; Burtey S
    BMC Nephrol; 2017 Jul; 18(1):251. PubMed ID: 28747155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the effectiveness of IV iron dosing for anemia management in common clinical practice: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Robinson BM; Larkina M; Bieber B; Kleophas W; Li Y; Locatelli F; McCullough KP; Nolen JG; Port FK; Pisoni RL
    BMC Nephrol; 2017 Nov; 18(1):330. PubMed ID: 29121874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low levels of serum ferritin lead to adequate hemoglobin levels and good survival in hemodialysis patients.
    Ogawa C; Tsuchiya K; Kanda F; Maeda T
    Am J Nephrol; 2014; 40(6):561-70. PubMed ID: 25592750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Switch from Ferric Gluconate to Ferric Carboxymaltose in Hemodialysis Patients Acts on Iron Metabolism, Erythropoietin, and Costs: A Retrospective Analysis.
    Lacquaniti A; Gargano R; Campo S; Casuscelli di Tocco T; Schifilliti S; Monardo P
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374275
    [No Abstract]   [Full Text] [Related]  

  • 9. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
    Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease].
    Romanet T; Bedouch P; Zaoui P
    Nephrol Ther; 2019 Apr; 15(2):104-109. PubMed ID: 30803900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
    Sibbel SP; Koro CE; Brunelli SM; Cobitz AR
    BMC Nephrol; 2015 Aug; 16():144. PubMed ID: 26283069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
    Schiller B; Bhat P; Sharma A
    Clin Ther; 2014 Jan; 36(1):70-83. PubMed ID: 24315802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
    Rognoni C; Ortalda V; Biasi C; Gambaro G
    Adv Ther; 2019 Nov; 36(11):3253-3264. PubMed ID: 31489572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of aggressively driven intravenous iron therapy on infectious complications in end-stage renal disease patients on maintenance hemodialysis.
    Bansal A; Sandhu G; Gupta I; Kalahalli S; Nayak R; Zouain E; Chitale RA; Meisels I; Chan G
    Am J Ther; 2014; 21(4):250-3. PubMed ID: 22832501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage.
    Kuragano T; Kitamura K; Matsumura O; Matsuda A; Hara T; Kiyomoto H; Murata T; Fujimoto S; Hase H; Joki N; Fukatsu A; Inoue T; Itakura Y; Nakanishi T
    PLoS One; 2016; 11(3):e0147328. PubMed ID: 26933949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study.
    Peters NO; Jay N; Cridlig J; Rostoker G; Frimat L
    BMC Nephrol; 2017 Mar; 18(1):97. PubMed ID: 28320343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis.
    Block GA; Mizani MR; Broumand V; Newby FD; Erinle A; Arias C; Block M; Brillhart S; Leppink A; Danese M; Dittrich M
    Am J Nephrol; 2024; 55(5):520-528. PubMed ID: 38972306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].
    Mpio I; Boumendjel N; Karaaslan H; Arkouche W; Lenz A; Cardozo C; Cardozo J; Pastural-Thaunat M; Fouque D; Silou J; Attaf D; Laville M
    Nephrol Ther; 2011 Jul; 7(4):229-36. PubMed ID: 21353659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia Management among Hemodialysis Patients with High Ferritin Levels.
    Einbinder Y; Agur T; Davidov K; Zitman-Gal T; Golan E; Benchetrit S
    Isr Med Assoc J; 2018 Jul; 20(7):405-411. PubMed ID: 30109787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.